64 Results for "

metastases

" in MedChemExpress (MCE) Product Catalog:
Products (64)

64 Results for "metastases" in MCE Product Catalog:

26
26 Publications Verification
Cat. No.: HY-13902
CAS No.: 1232416-25-9
Purity:  99.70%
Synonyms: VE-822; VX-970; M6620
Research Areas:  

Infection Metabolic Disease Cancer

Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
26
26 Publications Verification
Cat. No.: HY-13902A
CAS No.: 1428935-04-9
Synonyms: VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride
Research Areas:  

Neurological Disease Cancer

Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib hydrochloride blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-109566
CAS No.: 2089288-03-7
Purity:  99.22%
Synonyms: AZD1390
Research Areas:  

Cancer

Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535
CAS No.: 262438-43-7
ATN-161 is an antagonist of α5β1 integrin and αvβ3 integrin, as well as an inhibitor of fibrosis, an inhibitor of oxidative stress, a tight junction stabilizer, a mitochondrial integrity protector, an angiogenesis inhibitor and an antiviral agent. ATN-161 inhibits NLRP3, MAPK, and ROS. ATN-161 protects mice from SARS-CoV-2 infection . ATN-161 reduces infarct volume, alleviates edema, decreases immune cell infiltration, reduces the area of choroidal neovascularization lesions, lowers tumor microvessel density and viral load. ATN-161 can be used in research related to ischemic stroke, choroidal neovascularization, breast cancer, coronavirus disease 2019 (COVID-19), and liver metastasis of colorectal cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535A
CAS No.: 904763-27-5
Purity:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0037
CAS No.: 180916-16-9
Synonyms: CP-336156
Target:  

Estrogen Receptor/ERR

Research Areas:  

Inflammation/Immunology Cancer

Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0038
CAS No.: 190791-29-8
Synonyms: CP-336156 tartrate
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B0657A
CAS No.: 22560-50-5
Synonyms: Clodronate disodium salt
Target:  

Apoptosis

Research Areas:  

Metabolic Disease Cancer

Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99667
CAS No.: 1391727-24-4
Synonyms: OMP-54F28; FZD8-Fc

Target:  

Wnt

Research Areas:  

Cancer

Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-103316A
CAS No.: 874374-25-1
Purity:  99.92%
Target:  

Calcium Channel

Research Areas:  

Cardiovascular Disease Cancer

Ned 19 is a selective membrane-permeant non competitive NAADP antagonist and inhibits NAADP-mediated Ca 2+ signaling, with an IC50 of 65 nM . Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P5126
CAS No.: 1192362-32-5
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P5126A
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125399
CAS No.: 1366302-52-4
Purity:  99.74%
Synonyms: HBED-CC-PSMA
Research Areas:  

Cancer

PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-33299
CAS No.: 154235-77-5
Synonyms: BTCA
Research Areas:  

Cancer

Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .
loading...
    loading...
Cat. No.: HY-177475
CAS No.: 60701-99-7
Synonyms: 1-Arachidonoyl-sn-glycero-3-phosphocholine
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease Cancer

LysoPC 20:4 (20:4) (1-Arachidonoyl-sn-glycero-3-phosphocholine) is a serum metabolite. LysoPC 20:4 (20:4) decreases in tumor-bearing mice, but the reduction is not significant. LysoPC (20:4) can be used in cancer and obesity-related research .
loading...
    loading...
Cat. No.: HY-P99781
CAS No.: 1610761-46-0
Synonyms: MLN-1202

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-153450
CAS No.: 2308504-22-3
Purity:  99.75%
Research Areas:  

Cancer

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-159480
CAS No.: 2907782-78-7
Target:  

Src ATM/ATR Apoptosis mTOR AMPK

Research Areas:  

Cancer

AD1058 is an orally active, selective, and BBB-permeable inhibitor of ATR (IC50: 1.6 nM). AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases .
loading...
    loading...
Cat. No.: HY-114988
CAS No.: 24769-56-0
Synonyms: tetranor-PGEM
PGE-M (tetranor-PGEM) is a metabolite of Prostaglandin E2 (HY-101952) and also an inflammatory biomarker. Urinary PGE-M is a potential biomarker for detecting advanced colorectal tumors. PGE-M can be used in studies related to colorectal cancer, obesity, aging and breast cancer .
loading...
    loading...
Cat. No.: HY-P5362
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
loading...
    loading...